K Number
K170210
Manufacturer
Date Cleared
2017-09-01

(220 days)

Product Code
Regulation Number
876.1300
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.
• It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.
• It may be used in the visualization and monitoring in the small bowel of lesions that may be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.
• The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the small bowel. It is intended for use in adults.

PillCam Desktop Software 9.0 indications for use:
With PillCam SB 2/ SB 3 Capsule
The PillCam SB 2/ SB 3 capsule is intended for visualization of the small bowel mucosa.

  • It may be used in the visualization and monitoring of lesions that may indicate Crohn's disease not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be a source of obscure bleeding (either overt or occult) not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be potential causes of iron deficiency anemia (IDA) not detected by upper and lower endoscopy.
    The Suspected Blood Indicator (SBI) feature is intended to mark frames of the video suspected of containing blood or red areas.
    The PillCam SB 2/ SB 3 capsule may be used as a tool in the detection of abnormalities of the small bowel and is intended for use in adults and children from two years of age.

With PillCam UGI Capsule
The PillCam UGI capsule endoscopy system is intended for visualization of the upper gastrointestinal tract (esophagus, stomach, duodenum). It may be used for visualization of blood in the upper gastrointestinal tract (esophagus, stomach, duodenum) in patients who are hemodynamically stable and at least 18 years of age.

With PillCam COLON 2 Capsule
The PillCam COLON 2 capsule endoscopy system is intended to provide visualization of the colon. It may be used for detection of colon polyps in patients after an incomplete optical colonoscopy with adequate preparation, and a complete evaluation of the colon was not technically possible. In addition, it is intended for detection of colon polyps in patients with evidence of gastrointestinal bleeding of lower GI origin. This applies only to patients with major risks for colonoscopy or moderate sedation, but who could tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality was identified on capsule endoscopy.

With PillCam SBC Capsule
The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.

  • It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.
  • It may be used in the visualization and monitoring in the small bowel of lesions that may be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.
  • The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the small bowel. It is intended for use in adults.
Device Description

The PillCam SBC capsule endoscopy system is comprised of four main subsystems; (1) the ingestible PillCam SBC capsule, (2) the PillCam Recorder DR3, (3) the PillCam Software (a new version of the formerly branded "RAPID" software), and (4) the Workstation and/or accessories.

  1. Ingestible PillCam SBC Capsule
    The disposable, ingestible PillCam SBC Capsule is designed to acquire images during the natural propulsion through the digestive system. The capsule transmits the acquired images via a RF communication channel to the PillCam Recorder located outside the body.
  2. PillCam Recorder DR3
    The PillCam Recorder DR3 is an external receiving/recording unit that receives and stores the acquired images from the capsule.
  3. PillCam Software
    The PillCam Software (previously branded as "RAPID" Software) 9.0 is a software application that is utilized to process, analyze, store, and view the acquired images collected from the PillCam Recorder to create a video of the images. The software also includes a reporting function to create detailed clinical reports, in-service training videos, and patient instruction forms. PillCam Desktop Software 9.0 supports PillCam capsule endoscopy of the gastrointestinal (GI) tract with all PillCam video capsules (SB, COLON, UGI and SBC).
  4. Workstation and Accessories
    The Workstation is a modified standard personal computer that is the operational platform for the PillCam software. The Sensor array or sensor belt receive data from the PillCam capsule and transfer the data to the PillCam Recorder DR3.
AI/ML Overview

The provided text describes a 510(k) premarket notification for the PillCam SBC capsule endoscopy system and PillCam Desktop Software 9.0. It asserts substantial equivalence to predicate devices but does not contain a detailed study report with specific acceptance criteria and performance data in the format requested.

Therefore, I cannot extract the following information from the provided text:

  • A table of acceptance criteria and the reported device performance: The document states that the device "meets the guidance entitled 'Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging System; Final Guidance for Industry and FDA' dated November 28, 2001." and that "The proposed changes in this submission do not raise new performance or safety issues." However, it does not provide specific quantitative acceptance criteria or detailed reported performance against those criteria. It lists some "Bench Testing" but without numerical results or criteria.
  • Sample sizes used for the test set and the data provenance: No information is provided regarding the sample size of any test sets or whether data was retrospective or prospective, or its country of origin.
  • Number of experts used to establish the ground truth for the test set and the qualifications of those experts: This information is not present in the document.
  • Adjudication method for the test set: This information is not present.
  • If a multi-reader, multi-case (MRMC) comparative effectiveness study was done, and the effect size of how much human readers improve with AI vs without AI assistance: No mention of an MRMC study or AI assistance is made. The software's features focus on improving user viewing experience and providing tools for analysis.
  • If a standalone (i.e., algorithm only without human-in-the-loop performance) was done: The document does not describe standalone algorithm performance studies.
  • The type of ground truth used: The document does not specify the type of ground truth used for performance evaluation, beyond implying that the device's visualization capabilities are compared to existing diagnostic methods (e.g., endoscopy) as part of its intended use.
  • The sample size for the training set: No information about training sets is provided.
  • How the ground truth for the training set was established: No information about training sets is provided.

However, the document does contain information about performance data in a general sense:

Relevant Performance Data Mentioned:

The document mentions that the device "meets the guidance entitled 'Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging System; Final Guidance for Industry and FDA' dated November 28, 2001." This is the general regulatory standard the device aims to meet.

It also highlights that "The proposed changes in this submission do not raise new performance or safety issues."

Bench Testing:
The following bench tests were conducted or deemed applicable due to similarity with the predicate device (PillCam COLON 2 capsule):

  • Biting test
  • pH resistance test
  • Optical resolution
  • Optical verification including Field of View and depth of focus
  • Verification of frame rate (PillCam SBC capsule, PillCam Desktop Software 9.0)
  • Shelf life and battery evaluation (PillCam SBC capsule, PillCam Desktop Software 9.0)
  • Color reproducibility (PillCam SBC capsule, PillCam Desktop Software 9.0)
  • Image quality (PillCam SBC capsule, PillCam Desktop Software 9.0)

Software Validation:
PillCam Desktop Software 9.0 was validated and documented per FDA's software guidance document.

Optical Features:

  • 4 white LEDs per optical head are used as the SBC capsule illumination source.
  • The optical Field of view from the entrance pupil is 168°.
  • The Effective Visibility distance is set to 30mm. (These features are identical to the PillCam COLON 2 capsule).

In summary, while the document confirms that performance testing and validation were conducted to demonstrate substantial equivalence and adherence to regulatory guidance, it does not provide the detailed, quantitative breakdown of acceptance criteria and study results requested.

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines suggesting hair or movement.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

September 1, 2017

Given Imaging Ltd. Hilla Debby Director, Clinical & Regulatory 2 Hacarmel Stret, New Industrial Park, P.O. Box 258 Yokneam, 20692 Israel

Re: K170210 Trade/Device Name: PillCam SBC capsule endoscopy system, PillCam Desktop Software 9.0 Regulation Number: 21 CFR& 876.1300 Regulation Name: Ingestible Telemetric Gastrointestinal Capsule Imaging System Regulatory Class: II Product Code: NEZ, PGD Dated: July 24, 2017 Received: July 27, 2017

Dear Hilla Debby:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

Charles Viviano -S

For Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug AdministrationForm Approved: OMB No. 0910-0120Expiration Date: January 31, 2017See PRA Statement below.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Indications for Use

510(k) Number (if known)K170210
Device NamePillCam SBC capsule endoscopy system
Indications for Use (Describe)The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.• It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.• It may be used in the visualization and monitoring in the small bowel of lesions that may be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.• The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the small bowel. It is intended for use in adults.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."

FORM FDA 3881 (8/14)Page 1 of 1
-----------------------------------

PSC Publishing Services (301) 443-6740 EF

5

{3}------------------------------------------------

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below
510(k) Number (if known)K170210
Device NamePillCam Desktop Software 9.0

Indications for Use

Indications for Use (Describe)

With PillCam SB 2/ SB 3 Capsule
The PillCam SB 2/ SB 3 capsule is intended for visualization of the small bowel mucosa.

  • It may be used in the visualization and monitoring of lesions that may indicate Crohn's disease not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be a source of obscure bleeding (either overt or occult) not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be potential causes of iron deficiency anemia (IDA) not detected by upper and lower endoscopy.

The Suspected Blood Indicator (SBI) feature is intended to mark frames of the video suspected of containing blood or red areas.
The PillCam SB 2/ SB 3 capsule may be used as a tool in the detection of abnormalities of the small bowel and is intended for use in adults and children from two years of age.

With PillCam UGI Capsule
The PillCam UGI capsule endoscopy system is intended for visualization of the upper gastrointestinal tract (esophagus, stomach, duodenum). It may be used for visualization of blood in the upper gastrointestinal tract (esophagus, stomach, duodenum) in patients who are hemodynamically stable and at least 18 years of age.

With PillCam COLON 2 Capsule
The PillCam COLON 2 capsule endoscopy system is intended to provide visualization of the colon. It may be used for detection of colon polyps in patients after an incomplete optical colonoscopy with adequate preparation, and a complete evaluation of the colon was not technically possible. In addition, it is intended for detection of colon polyps in patients with evidence of gastrointestinal bleeding of lower Gl origin. This applies only to patients with major risks for colonoscopy or moderate sedation, but who could tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality was identified on capsule endoscopy.

With PillCam SBC Capsule
The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.

  • It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.
  • It may be used in the visualization and monitoring in the small bowel of lesions that may be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.
  • The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the small bowel. It is intended for use in adults.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)

FORM FDA 3881 (8/14)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
Page 1 of 26

{4}------------------------------------------------

. WOJER SSARIOA JIAMS ATATS ARA SHT OT MAO9 GETTIJAMOS AUOY CHAS TON OCT 2001 to to to to hollows and to singmeniuper of your seilede notices sidi

ələqmədin və bəstəsində inin bilindən bir nəzərində inzibati ərazisindən məlumatı əsasən ən əmi əri gəlbərin və qalında və sənədlər və bir müsamətini in noticəllər və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir və bir

ວ່າ ,ກອນານປ ຍ່າປີ ຄຸນາ ຄຸນບໍ່ໄຂອງບູນຂ ຄຸນເ່ນນໄວກ່ ,ບຸດປະຈຸບວນ ແດ່ງສາຫາດໃນປະເທດໄທ່ ຢາກ Food bus Only Anninistration Download the alth and Human Services

้า ที่ต้อง ค.ศ. ของ รับน

{5}------------------------------------------------

510(k) Summary

I. SUBMITTER

Submitter Name and Address:Given Imaging Ltd. (GI Solutions, Medtronic)
2 Hacarmel Street
New Industrial Park
PO Box 258
Yokneam 20692
Israel
Tel.: 011-972-4-9097774
Fax: 011-972-73-2501533
Contact Person:Hilla Debby
Director, Clinical & Regulatory
Email: Hilla.Debby@medtronic.com
Phone Number:972 (4) 909-7774
Fax Number:(972) 73-2501533
Establishment Registration Number:9710107
Date Prepared:September 1, 2017
II. DEVICE
Device Trade Name(s):PillCam SBC capsule endoscopy system, PillCamDesktop Software 9.0
Device Common Name:Ingestible telemetric gastrointestinal capsule imagingsystem
Classification:Regulation No: 876.1300, Class: IIPanel: Gastroenterology/UrologyNEZ - System, Imaging, Gastrointestinal, Wireless,CapsulePGD – Colon Capsule Imaging System

{6}------------------------------------------------

III. PREDICATE DEVICE(S)

  • Given PillCam® SB 3 capsule endoscopy system and Given PillCam® endoscopy ● system with RAPID® 8.0 (K123864) – Primary Predicate
  • . PillCam® COLON 2 capsule endoscopy system (K153466) – Additional Predicate

DEVICE DESCRIPTION: IV.

The PillCam SBC capsule endoscopy system is comprised of four main subsystems; (1) the ingestible PillCam SBC capsule, (2) the PillCam Recorder DR3, (3) the PillCam Software (a new version of the formerly branded "RAPID" software), and (4) the Workstation and/or accessories.

    1. Ingestible PillCam SBC Capsule
      The disposable, ingestible PillCam SBC Capsule is designed to acquire images during the natural propulsion through the digestive system. The capsule transmits the acquired images via a RF communication channel to the PillCam Recorder located outside the body.
  • PillCam Recorder DR3 2.
    The PillCam Recorder DR3 is an external receiving/recording unit that receives and stores the acquired images from the capsule.

    1. PillCam Software
      The PillCam Software (previously branded as "RAPID" Software) 9.0 is a software application that is utilized to process, analyze, store, and view the acquired images collected from the PillCam Recorder to create a video of the images. The software also includes a reporting function to create detailed clinical reports, in-service training videos, and patient instruction forms. PillCam Desktop Software 9.0 supports PillCam capsule endoscopy of the gastrointestinal (GI) tract with all PillCam video capsules (SB, COLON, UGI and SBC).
  • Workstation and Accessories 4.
    The Workstation is a modified standard personal computer that is the operational platform for the PillCam software. The Sensor array or sensor belt receive data from the PillCam capsule and transfer the data to the PillCam Recorder DR3.

{7}------------------------------------------------

V. INDICATIONS FOR USE:

The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.

  • · It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.
  • It may be used in the visualization and monitoring in the small bowel of lesions that may . be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.
  • The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the . small bowel. It is intended for use in adults.

PillCam Desktop Software 9.0 indications for use:

With PillCam SB 2/ SB 3 Capsule

The PillCam SB 2/ SB 3 capsule is intended for visualization of the small bowel mucosa.

  • It may be used in the visualization and monitoring of lesions that may indicate Crohn's ● disease not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be a source of ● obscure bleeding (either overt or occult) not detected by upper and lower endoscopy.
  • It may be used in the visualization and monitoring of lesions that may be potential . causes of iron deficiency anemia (IDA) not detected by upper and lower endoscopy.

The Suspected Blood Indicator (SBI) feature is intended to mark frames of the video suspected of containing blood or red areas.

The PillCam SB 2/ SB 3 capsule may be used as a tool in the detection of abnormalities of the small bowel and is intended for use in adults and children from two years of age.

With PillCam UGI Capsule

The PillCam UGI capsule endoscopy system is intended for visualization of the upper gastrointestinal tract (esophagus, stomach, duodenum). It may be used for visualization of

{8}------------------------------------------------

blood in the upper gastrointestinal tract (esophagus, stomach, duodenum) in patients who are hemodynamically stable and at least18 years of age.

With PillCam COLON 2 Capsule

The PillCam COLON 2 capsule endoscopy system is intended to provide visualization of the colon. It may be used for detection of colon polyps in patients after an incomplete optical colonoscopy with adequate preparation, and a complete evaluation of the colon was not technically possible. In addition, it is intended for detection of colon polyps in patients with evidence of gastrointestinal bleeding of lower GI origin. This applies only to patients with major risks for colonoscopy or moderate sedation, but who could tolerate colonoscopy and moderate sedation in the event a clinically significant colon abnormality was identified on capsule endoscopy.

With PillCam SBC Capsule

The PillCam SBC capsule is intended for visualization of the small bowel and colonic mucosa.

  • · It may be used in the visualization and monitoring of lesions in the small bowel that may indicate Crohn's disease not detected by upper and lower endoscopy, and for the visualization of inflammation of the colon in patients with colonoscopy-diagnosed Crohn's disease.
  • · It may be used in the visualization and monitoring in the small bowel of lesions that may be a source of obscure bleeding (either overt or occult) or that may be potential causes of iron deficiency anemia (IDA) not detected by initial upper and lower endoscopy.
  • · The PillCam SBC capsule may be used as a tool in the detection of abnormalities of the small bowel. It is intended for use in adults.

VI. TECHNOLOGICAL CHARACTERISTICS:

The technological characteristics are similar to the predicate device, PillCam COLON 2 capsule endoscopy system. The only difference between PillCam SBC capsule and PillCam COLON 2 capsule is the programming of the Adaptive Frame Rate (AFR).

Regarding PillCam Desktop Software 9.0, the main difference as compared to previous software versions is the support of PillCam SBC capsule endoscopy procedures, some minor

{9}------------------------------------------------

improvements to existing tools and an improved user interface and complimentary tools. These tools include: improved viewing mode (demonstrated by collage view capability), Dynamic Player Control, enhanced atlas that provides reference images, a tool to aid in ulcer size estimation. GI Map which provides a graphical representation of the small bowel and colon and the progress of the capsule and a tool that displays the 100 most clinically relevant images. The features of PillCam Desktop Software 9.0 create a user-friendly software which may enhance user's viewing experience. None of the presented changes raise any new safety issues.

VII. PERFORMANCE DATA:

The device meets the guidance entitled "Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging System; Final Guidance for Industry and FDA" dated November 28, 2001.

The proposed changes in this submission do not raise new performance or safety issues.

Optical Features

4 white LEDs per optical head are used as the SBC capsule illumination source. The optical Field of view from the entrance pupil is 168° and the Effective Visibility distance is set to 30mm. features are identical as PillCam COLON 2 capsule.

Bench Testing

Since PillCam SBC capsule and the COLON 2 capsule predicate device are identical in terms of external components and technology, the following tests have been verified on PillCam COLON 2 and are applicable for PillCam SBC capsules as well:

  • . Biting test
  • pH resistance test .
  • . Optical resolution
  • Optical verification including field of View and depth of focus ●

Additional bench test that were conducted with PillCam SBC capsule, PillCam Desktop Software 9.0 are:

  • . Verification of frame rate

{10}------------------------------------------------

  • Shelf life and battery evaluation ●
  • Color reproducibility ●
  • Image quality

In addition, PillCam Desktop Software 9.0 was validated and documented per FDA's software guidance document.

VIII. CONCLUSION:

Based on the technological characteristics of the devices, GI Solutions believes that the PillCam SBC capsule, PillCam Desktop Software 9.0 and the predicate devices selected are substantially equivalent and do not raise new issues of safety or effectiveness.

§ 876.1300 Ingestible telemetric gastrointestinal capsule imaging system.

(a)
Identification. An ingestible telemetric gastrointestinal capsule imaging system is used for visualization of the small bowel mucosa as an adjunctive tool in the detection of abnormalities of the small bowel. The device captures images of the small bowel with a wireless camera contained in a capsule. This device includes an ingestible capsule (containing a light source, camera, transmitter, and battery), an antenna array, a receiving/recording unit, a data storage device, computer software to process the images, and accessories.(b)
Classification. Class II (special controls). The special control is FDA's guidance, “Class II Special Controls Guidance Document: Ingestible Telemetric Gastrointestinal Capsule Imaging Systems; Final Guidance for Industry and FDA.”